CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced the successful completion of a new financing round, raising nearly RMB 100 million (USD 13.8 million). This funding round was led by prominent investors Yifeng Capital and Zhiyi Investment, with additional participation from Yuanhe Holdings and the Suzhou Park Science and Technology Innovation Fund. The capital raised is intended to enhance CATUG Bio’s overseas business operations and bolster its comprehensive CRDMO (Contract Research, Development, and Manufacturing Organization) service capabilities, thereby reinforcing the company’s competitive edge in nucleic acid drug technology.
Founded in 2021, CATUG Bio is dedicated to offering a one-stop CRDMO service for the global nucleic acid and gene therapy industry, covering the entire spectrum from drug research and development to quality research, clinical application, and industrialization. The company boasts four core technology service platforms, which include high-quality large-scale plasmid process development and production, mRNA synthesis and delivery full process development and production, and nucleic acid analysis methods and quality research. CATUG Bio has established operating bases in China, the United States, and Switzerland, along with research and development centers and GMP industrialization bases in Suzhou and Wuhan.- Flcube.com
